A5027699430- Economic and Financial Impacts of Cancer
- Health Systems, Economic Evaluations, Quality of Life
- Neutropenia and Cancer Infections
- Cancer Treatment and Pharmacology
- Ethics in Clinical Research
- BRCA gene mutations in cancer
- Genetic factors in colorectal cancer
- Clinical practice guidelines implementation
- Ovarian cancer diagnosis and treatment
- Cancer Genomics and Diagnostics
- Cancer survivorship and care
- Childhood Cancer Survivors' Quality of Life
- Telemedicine and Telehealth Implementation
- Mental Health and Patient Involvement
- Biomedical Ethics and Regulation
- Clinical Laboratory Practices and Quality Control
- Social Media in Health Education
- Family Support in Illness
- Reproductive Biology and Fertility
- Pancreatic and Hepatic Oncology Research
- Prenatal Screening and Diagnostics
- Mycobacterium research and diagnosis
- Endometrial and Cervical Cancer Treatments
- Pharmaceutical Economics and Policy
- Bacterial Identification and Susceptibility Testing
Fred Hutch Cancer Center
2014-2024
Patient Advocate Foundation
2017
Swedish Medical Center
2015
Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa
2014
Cancer Research Center
2014
Few studies have reported on interventions to alleviate financial toxicity in patients with cancer. We developed a navigation program collaboration our partners, Consumer Education and Training Services (CENTS) Patient Advocate Foundation (PAF), improve patient knowledge about treatment costs, provide counseling, help manage out-of-pocket expenses. conducted pilot study assess the feasibility impact of this program.Patients cancer received education course followed by monthly contact CENTS...
Few studies have engaged patients and caregivers in interventions to alleviate financial hardship. We collaborated with Consumer Education Training Services (CENTS), Patient Advocate Foundation (PAF), Family Reach (FR) assess the feasibility of enrolling patient-caregiver dyads a program that provides counseling, insurance navigation, assistance medical cost living expenses.Patients solid tumors aged ≥18 years their primary caregiver received education video, monthly contact CENTS counselor...
The Fred Hutchinson Cancer Research Center has engaged an External Stakeholder Advisory Group (ESAG) in the planning and implementation of TrACER Study (S1415CD), a five-year pragmatic clinical trial assessing effectiveness guideline-based colony stimulating factor standing order intervention. is being conducted by SWOG through National Institute Community Oncology Program 45 clinics. ESAG includes ten patient partners, two payers, pharmacists, guideline experts, four providers one medical...
Abstract Background Cancer-related financial hardship is a side effect of cancer diagnosis and treatment, affects both patients caregivers. Although many oncology clinics have increased navigation services, few resources to proactively provide counseling assistance families affected by before occurs. As part an ongoing randomized study testing proactive intervention, S1912CD, among sites the National Cancer Institute Community Oncology Research Program (NCORP), we conducted baseline survey...
Abstract Purpose Many cancer patients and caregivers experience financial hardship, leading to poor outcomes. Gastric gastroesophageal junction (GEJ) are particularly at risk for hardship given the intensity of treatment. This pilot randomized study among gastric/GEJ tested a proactive navigation (FN) intervention obtain signal efficacy inform larger, more rigorous study. Methods We 3-month FN compared usual care. Caregiver participation was optional. The primary endpoint incidence defined...
Serum markers are used before pelvic imaging to improve specificity and positive predictive value (PPV) of ovarian cancer multimodal screening strategies.We conducted a randomized controlled pilot trial estimate surgical PPV "2 3 tests positive" rule, compare use HE4 as first-line (Arm 1) versus second-line 2) screen, in women at high elevated risk for epithelial (EOC) five study sites. Semiannual was offered 208 ages 25 80 years with deleterious BRCA germline mutations 834 35 pedigrees...
Women with a documented deleterious mutation in BRCA1 or BRCA2 are at substantially elevated risk for ovarian cancer. To understand what percentage of women high-risk family histories know their is we surveyed 1,885 high- moderate-risk history and no personal breast cancer, asked about perceived Among women, fewer than 20% reported use genetic counseling, knowledge cancer was low. Prior counseling associated greater Results suggest that most (>75%) do not Identification potentially referral...
PURPOSE: Biomarker-driven master protocols represent a new paradigm in oncology clinical trials, but their complex designs and wide-ranging genomic results returned can be difficult to communicate participants. The objective of this pilot study was evaluate patient knowledge expectations related return the Lung Cancer Master Protocol (Lung-MAP). METHODS: Eligible participants with previously treated advanced non–small-cell lung cancer were recruited from patients enrolled Lung-MAP....
BACKGROUND Guidelines recommend genetic counseling and testing for women who have a pedigree suggestive of an inherited susceptibility ovarian cancer. The authors evaluated the effect referral to on prophylactic oophorectomy in randomized controlled trial. METHODS Data from electronic mammography reporting system identified 12,919 with that included breast cancer, whom 625 were had high risk cancer using risk‐assessment questionnaire. Of these, 458 provided informed consent 1:1 intervention...
Primary prophylactic colony-stimulating factors (PP-CSFs) are prescribed to reduce febrile neutropenia (FN) but their benefit for intermediate FN risk regimens is uncertain. Within a pragmatic, randomized trial of standing order entry (SOE) PP-CSF intervention, we conducted substudy evaluate the effectiveness SOE patients receiving intermediate-risk regimens.
Importance Colony-stimulating factors are prescribed to patients undergoing chemotherapy reduce the risk of febrile neutropenia. Research suggests that 55% 95% colony-stimulating factor prescribing is inconsistent with national guidelines. Objective To examine whether a guideline-based standing order for primary prophylactic improves use and reduces incidence Design, Setting, Participants This cluster randomized clinical trial, Trial Assessing CSF Prescribing Effectiveness Risk (TrACER),...
174 Background: Few studies have reported on interventions to alleviate financial toxicity (FT) in cancer patients (pts) and informal caregivers (cgs). We developed a navigation program collaboration with Consumer Education Training Services (CENTS), Patient Advocate Foundation (PAF), Family Reach (FRF), offer coaching, insurance navigation, assistance unpaid non-medical bills. conducted pilot study assess feasibility of enrolling cgs pts describe the provided. Methods: Pts any stage solid...
We conducted a pragmatic, cluster-randomized trial to test whether guideline-based standing order entry (SOE) improves use of primary prophylactic CSF (PP-CSF) prescribing for patients receiving myelosuppressive chemotherapy. investigated variability in adherence the intervention.
Abstract Background Cancer Care Delivery (CCD) research studies often require practice-level interventions that pose challenges in the clinical trial setting. The SWOG Research Network (SWOG) conducted S1415CD, one of first pragmatic cluster-randomized CCD trials to be implemented through National Institute (NCI) Community Oncology Program (NCORP), compare outcomes primary prophylactic colony stimulating factor (PP-CSF) use for an intervention automated PP-CSF standing orders usual care....
Aim: Stakeholder engagement is central to comparative effectiveness research yet there are gaps in definitions of success. We used a framework developed by Lavallee et al. defining effective criteria evaluate stakeholder during pragmatic cluster-randomized trial. Methods: Semi-structured interviews were from the and completed learn about members' experiences. Interviews analyzed deductive approach for themes related criteria. Results: Thirteen members participated described: respect ideas,...
60 Background: The S1415CD intervention requires the integration of guideline-based prescribing recommendations and standing orders for primary prophylactic colony stimulating factors into existing chemotherapy order systems at community practices within National Cancer Institute’s Community Oncology Research Program. We looked impact clinic level characteristics on length time needed to successfully adopt subsequent patient accrual. Methods: calculated between randomization completion each...
1518 Background: Primary prophylactic colony stimulating factors (PP-CSF) are prescribed to patients undergoing chemotherapy reduce the risk of febrile neutropenia (FN) but their benefit for regimens with intermediate FN is uncertain. Within a pragmatic, randomized trial standing order entry (SOE) intervention prescribing PP-CSF, we designed substudy evaluate effectiveness PP-CSF receiving therapy risk. Methods: TrACER was cluster where NCI community Oncology Research Program practices were...
1525 Background: Primary prophylactic colony stimulating factors (PP-CSF) are prescribed to patients undergoing chemotherapy reduce the risk of febrile neutropenia (FN). Prior studies have shown that 55-95% CSF prescribing is inconsistent with practice guidelines. We conducted a cluster randomized trial determine if guideline-informed standing orders for PP-CSF improved and reduced incidence FN. Methods: Patients age ≥18 breast, colorectal or non-small cell lung cancer initiating first...
Abstract Objectives: Information technology provides an opportunity for systematic identification of high-risk patients appropriate referral. We conducted a randomized controlled trial to test whether routine women at high risk epithelial ovarian cancer using electronic database and subsequent referral genetic counseling would promote testing prophylactic surgery. Methods: Electronic data in mammography reporting system from large community hospital Seattle was used identify increased based...
Background/Aims: Systematically identifying and referring women at high risk of hereditary breast ovarian cancer to genetic counseling may minimize disparities in services utilization. Our aims were examine the effect systematic referral on changes testing-related cognitions utilization test for effect-modification by education level.
1527 Background: Cancer patients with Medicaid insurance have a 50% higher risk of unplanned ED admissions during systemic chemotherapy compared to commercially insured cancer patients. In prospective study an ePRO app and smartwatch remotely monitor receiving anti-cancer therapy, we symptoms biometric data among financially fragile (able vs. not come up $2000 in 30 days for unexpected expense) enrollees solid tumor malignancies. Methods: The was conducted at 3 community oncology practices...
Abstract BACKGROUND Among the 400,000 individuals undergoing chemotherapy for breast, colorectal and lung cancer in US, many are at risk of febrile neutropenia (FN). Prophylactic colony stimulating factor (CSF) use reduces FN, yet studies show that 55%-95% CSF prescribing is inconsistent with clinical practice guidelines. There lack evidence ambiguous guidelines regimens an intermediate FN. To address these issues, we conducting a pragmatic trial to assess generate about efficacy regimens....
e18079 Background: Although financial toxicity is associated with poorer clinical outcomes in cancer survivors, few studies have attempted to address this toxicity. We developed a navigation program collaboration our partners (Consumer Education and Training Services (CENTS) Patient Advocate Foundation (PAF)) improve patients’ knowledge about treatment costs, provide counseling, help out-of-pocket expenses. conducted pilot study assess feasibility early impact of program. Methods: Patients...
57 Background: SWOG S1415CD (NCT02728596) is a pragmatic trial comparing outcomes of colony stimulating factor (CSF) use in usual care with that uses guideline-informed standing CSF orders for protocol chemotherapy regimens. To develop the regimen list, we reviewed, reconciled, and compiled comprehensive list 77 NCCN-recognized core regimens 40 biologic variants breast, non-small cell, colorectal cancer, meant to capture broad population variety practices settings. The 24 intervention sites...